drugset / Trial / NCT00141011

Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke

NCT00141011 ↗

Phase 3 Terminated 277 enrolled Neurobiological Technologies
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary purpose of this study is to determine whether a brief intravenous infusion of ancrod started within 6 hours of stroke onset improves functional outcome at 3 months.

Timeline

Start
2005-09
Primary completion
2008-12
Completion
2008-12

Outcome

Outcome not reported

Stopped: “Futility”

Drugs

EvaluationDrugModalityDoseRoute
Subject Ancrod Unknown 0.167 iu/kg Intravenous